Fed. Circ. Affirms Stay Extension In Evista Dispute
A federal appeals court has upheld an extension to the 30-month stay preventing approval of Teva Pharmaceuticals USA Inc.'s proposed generic for osteoporosis drug Evista until an infringement trial with Eli...To view the full article, register now.
Already a subscriber? Click here to view full article